Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026.

NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today an exclusive ...

Some antidepressants, such as fluoxetine (Prozac), work by preventing neurons from vacuuming up the neurotransmitter serotonin from the gaps between brain cells—a process called reuptake. By doing so, ...

Bupropion (BUP) is a dopamine (DA) and norepinephrine (NE) reuptake inhibitor that causes mild weight loss in obese adults. Subchronic (7 day) coadministration of selective DA and NE reuptake ...

The obvious answer has been that it's because they selectively block the reuptake of serotonin. This explanation is appealing because of its simplicity; however, as is so often true of explanations ...

Immediately following Robert F. Kennedy Jr.’s confirmation as health secretary, President Donald Trump instructed his administration to assess the “threat” posed to children by the prescription of ...

Although originally developed as an antidepressant, long-term bupropion (BUP) treatment was recently shown to cause 5–8% weight loss over placebo in clinical trials with obese adults. BUP's ...